手术视频
关于我们
联系我们
中心官网
泌尿系统常见疾病循证医学证据
首页
良性前列腺增生
泌尿系统感染
泌尿系统结石
前列腺炎
前列腺癌
膀胱肿瘤
肾癌
其他
首页
搜索结果
证据分类
良性前列腺增生
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
手术视频
调查问卷
泌尿系统感染
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
泌尿系统结石
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺炎
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
膀胱肿瘤
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
肾癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
其他
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
搜索结果
按关键字
按标题
按关键词
按摘要
按作者
按期刊
共搜索到
10条
与
Medicine
有关的结果
Clinical Practice Guidelines for Bladder Cancer 2019 Update by the Japanese Urological Association: Summary of the Revision
2020年 发布于
Int J Urol
27卷 第9期
Japanese Urological Association
Bladder Cancer
Clinical Practice Guideline
Diagnosis
Evidenced-based
Medicine
Treatment.
文献简介
原文链接
Clinical Practice Guidelines for Bladder Cancer 2019 Update by the Japanese Urological Association: Summary of the Revision
2020年 发布于
International Journal of Urology
27卷 第9期
Japanese Urological Association
Bladder Cancer
Clinical Practice Guideline
Diagnosis
Evidenced-based
Medicine
Treatment.
文献简介
原文链接
Therapeutic efficacy of orally administered pollen for nonallergic diseases: An umbrella review
2019年 发布于
Phytother Res
33卷 第11期
Antonelli
M. Donelli
D. Firenzuoli
F.
Administration
Oral
Chronic Disease
Flowers/physiology
Humans
Male
Medicine
Traditional
Phytotherapy
Plant Extracts/*administration & dosage
Pollen/*physiology
Prostatic Hyperplasia/drug therapy
Prostatitis/drug therapy
Treatment Outcome
clinical practice
efficacy
evidence-based complementary and alternative medicine
phytotherapy
pollen
review
文献简介
原文链接
The Effect of Metformin on Bladder Cancer Incidence and Outcomes: A Systematic Review and Meta-Analysis
2022 年 发布于
Urol Oncol
46 卷 第 2 期
van Hattum J. W.
de Ruiter B.
Oddens J. R.
de Reijke T. M.
Wilmink J. W.
Molenaar R. J.
*Carcinoma
Transitional Cell/drug therapy
Humans
Organoids
Precision
Medicine
*Urinary Bladder Neoplasms/drug therapy
Urothelium/pathology
Metastases
Personalized medicine
Stem cells
Transurethral resection
文献简介
原文链接
Novel Visualization Methods Assisted Transurethral Resection for Bladder Cancer: An Updated Survival-Based Systematic Review and Meta-Analysis
2021 年 发布于
Plos One
23 卷 第 2 期
Li H.
Cao Y.
Ma P.
Ma Z.
Li C.
Yang W.
Zhou L.
*Clinical Protocols
*Cystectomy/methods
*Enhanced Recovery After Surgery
Humans
Time Factors
Treatment Outcome
Urinary Bladder Neoplasms/*surgery
Cystectomy
Eras
Fast track
Meta-analysis
Protocol
Systematic review
evidence-based medicine
文献简介
原文链接
lncRNA-UCA1 in the diagnosis of bladder cancer A meta-analysis
2021 年 发布于
Translational Andrology and Urology
2021 卷 第 2 期
Ding Z. S.
Ying W. W.
He Y. H.
Chen X.
Jiao Y. T.
Wang J. F.
Zhou X. F.
Adjuvants
Immunologic/therapeutic use
BCG Vaccine/therapeutic use
Evidence-Based
Medicine
Humans
Neoplasm Invasiveness
Neoplasm Recurrence
Local/*therapy
Treatment Outcome
Urinary Bladder Neoplasms/pathology/*therapy
Bacillus Calmette-Guerin unresponsive
Bladder preservation therapy
Bladder sparing
Non–muscle-invasive bladder cancer
文献简介
原文链接
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text
2021 年 发布于
Can Urol Assoc J
15 卷 第 8 期
Bhindi B.
Kool R.
Kulkarni G. S.
Siemens D. R.
Aprikian A. G.
Breau R. H.
Brimo F.
Fairey A.
French C.
Hanna N.
Izawa J. I.
Lacombe L.
McPherson V.
Rendon R. A.
Shayegan B.
So A. I.
Zlotta A. R.
Black P. C.
Kassouf W.
Guidelines as Topic
Humans
Immunotherapy/*methods
Societies
Medical/*standards
Urinary Bladder Neoplasms/*drug therapy
antineoplastic protocols
immunotherapy
urinary bladder neoplasms
urologic neoplasms
Pfizer
AstraZeneca
Nektar
Seattle Genetics
DragonFly Therapeutics
Non-CME
services: Genentech
AstraZeneca
Merck
Seattle Genetics
Contracted research:
Genentech
Merck
AstraZeneca
Nektar
Seattle Genetics
Immunomedics.
PCB─Consulting fees: AbbVie
Asieris Pharmaceuticals
Astellas
AstraZeneca
Bayer
Biosyent
Bristol-Myers Squibb
EMD Serono
Ferring
Fergene
H3
Biomedicine
Janssen
Merck
Roche
Sanofi
TerSera
Urogen
Contracted research:
iProgen. MTC─Consulting fees: Pfizer
EMD Serono
AstraZeneca
Exelixis
Eisai
Seattle Genetics
Astellas
Contracted research: Exelixis
Pfizer/EMD Serono
Janssen
Apricity Health. GSD─Participant/unpaid volunteer: HealthVibe focus
group 2020. MDG─Consulting fees: Inovio
NuMab
Janssen
Merck
GlaxoSmithKline
Genentech
Bristol-Myers Squibb
Seattle Genetics
Dracen
Dragonfly
Astellas
Novartis
Pfizer
AstraZeneca
Incyte
Dendreon
Eli Lilly
EMD Serono
Aileron
Therapeutics
Ownership interest: Rappta Therapeutics
NPI: 1639140668.
PG─Consulting fees: AstraZeneca
Dyania Health
EMD Serono
Immunomedics
Janssen
Merck
Mirati Therapeutics
Genentech
Pfizer
Seattle Genetics
Contracted Research: Bavarian Nordic
Bristol-Myers Squibb
Clovis Oncology
Debiopharm
Immunomedics
Pfizer
Merck
QED Therapeutics
GlaxoSmithKline
Kure
It Cancer Research
Mirati Therapeutics. SG─Consulting fees: Merck
Bristol-Myers
Squibb
Janssen
Seattle Genetics
AstraZeneca
Contracted research:
Bristol-Myers Squibb
Pfizer
Non-CME services: Exelixis. CJH─Consulting fees:
Astellas
Bristol-Myers Squibb
Genentech
Merck
Eisai
Seattle Genetics
2bPrecise
Non-CME services: Astellas
Bristol-Myers Squibb
Genentech
Eisai
Seattle Genetics. AMK─Consulting fees: Abbott Molecular
Arquer
ArTara
Asieris
AstraZeneca
BioClin Therapeutics
Bristol-Myers Squibb
Cepheid
Cold Genesys
Eisai
Engene
Inc.
Ferring
FerGene
Imagin
Janssen
MDxHealth
Medac
Merck
Pfizer
Photocure
ProTara
Roviant
Seattle Genetics
Sessen Bio
Theralase
TMC
Innovation
US Biotest
Contracted research: Adolor
Bristol-Myers Squibb
FKD
Industries
Heat Biologics
Merck
Photocure
SWOG/NIH
SPORE
AIBCCR
Clinical
trials: FKD
Merck
Bristol-Myers Squibb
Photocure
SWOG
Adolor
Heat
Biologics
Laboratory research: NIH
SPORE
AIBCCR
Educational grant: CEC
Oncology
Editorial board: European Urology Oncology
Journal of Urology
UroToday
President of organization: International Bladder Cancer Network (IBCN)
International Bladder Cancer Group (IBCG)
IP Rights: CyPRIT (Cytokine Predictors
of Response to Intravesical Therapy) Joint with UT MD Anderson Cancer Center.
LPL─Consulting fees: Pfizer Advisory Nursing board
2018
Lecture/Speaker/Expert
Panel: ASCO Bladder Program 2019
Pfizer learning day 2019
ASCO Bladder Program
Panel Member and Faculty 2019
Pfizer Learning Day Speaker 2019
BCAN Webinar
Faculty 11/2020. JJM─Consulting fees: AstraZeneca
Ferring
Janssen
Nucleix
Foundation
Medicine
Contracted research: Epizyme
Tesaro
Abbvie
Teaching an
endoscopy course: Olympus. ERP─Consulting fees: AstraZeneca
Infinity Pharma
Pfizer
Flatiron
Genentech
Merck
Seattle Genetics
Contracted research:
Astellas
Bristol-Myers Squibb
Genentech
Merck. JER─Consulting fees: Merck
Bristol-Myers Squibb
AstraZeneca
Astellas
Seattle Genetics
Boehringer
Ingelheim
Bayer
Pfizer
Roche/Genentech
Mirati
QED Therapeutics
Janssen
Pharmacyclics
GlaxoSmithKline
Contracted research/Clinical trial funding:
Seattle Genetics
Astellas
Roche/Genentech
Bayer
AstraZeneca
QED
Therapeutics. NS─Consulting fees: Amgen
Astellas
AstraZeneca
Bayer
Bristol-Myers Squibb
Dendreon
Fergene
Ferring
Janssen
Merck
Myovant
Nymox
Pfizer
Sanofi/Genzyme
Sesen Bio
Sun Pharma
Tolmar. GDS─Consulting fees:
Merck
Janssen
Ferring
Bristol-Myers Squibb
Pfizer
Genentech
Epivax
Oncology
AstraZeneca
Fidia
Cold Genesys
EnGene Bio
Aduro Biotech
Dendreon
FKD Therapies
CiClomed
Seattle Genetics
Urogen
PhotoCure. SITC staff:
SMW—Shares owned: Pacific Biosciences
Editas
Medicine
EG
AK
BL
LL─Nothing to
disclose.
文献简介
原文链接
ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update
2021 年 发布于
J Am Coll Radiol
18 卷 第 5s 期
Allen B. C.
Oto A.
Akin O.
Alexander L. F.
Froemming A. T.
Fulgham P. F.
Halpern D. J.
Gettle L. M.
Maranchie J. K.
Patel B. N.
Patlas M. N.
Schieda N.
Solanki A.
Turkbey I. B.
Venkatesan A. M.
Yoo D. C.
Lockhart M. E.
*Carcinoma
Transitional Cell
Evidence-Based
Medicine
Humans
*Radiology
Societies
Medical
United States
*Urinary Bladder Neoplasms/diagnostic imaging
Auc
Appropriate Use Criteria
Appropriateness Criteria
Bladder cancer
Muscle invasive bladder cancer
Nonmuscle invasive bladder cancer
Surveillance
Transitional cell carcinoma
Urothelial cancer
文献简介
原文链接
Sentinel Node Biopsy in Urothelial Carcinoma of the Bladder: Systematic Review and Meta-Analysis
2019 年 发布于
International Journal of Radiation Oncology Biology Physics
89 卷 第 8 期
Zarifmahmoudi L.
Ghorbani H.
Sadri K.
Tavakkoli M.
Keshvari M.
Salehi M.
Sadeghi R.
Animals
Cattle
Diet/*adverse effects
*Evidence-Based
Medicine
Food
Preserved/*adverse effects
Humans
Incidence
Meat/*adverse effects
Meat Products/*adverse effects
Reproducibility of Results
Risk Factors
Sheep
Domestic
Sus scrofa
Urinary Bladder Neoplasms/epidemiology/*etiology
Bladder cancer
Dose–response
Meta-analysis
Processed meat
Red meat
文献简介
原文链接
Association between obesity and bladder cancer recurrence: A meta-analysis
2018 年 发布于
J Cancer Res Ther
45 卷 第 15 期
Lin Y.
Wang Y.
Wu Q.
Jin H.
Ma G.
Liu H.
Wang M.
Zhang Z.
Chu H.
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Chemotherapy
Adjuvant
Cisplatin/administration & dosage
*Cystectomy/methods
Evidence-Based
Medicine
Humans
*Lymph Node Excision
Neoadjuvant Therapy/*methods
Neoplasm Invasiveness
Organ Sparing Treatments/methods
Randomized Controlled Trials as Topic
Survival Analysis
Treatment Outcome
Urinary Bladder Neoplasms/mortality/*pathology/*therapy
adjuvant chemotherapy
bladder cancer
bladder-sparing therapy
lymph node dissection
neoadjuvant chemotherapy
radical cystectomy
文献简介
原文链接